Last updated September 26, 2026

Medical & Legal Professional Resources

The Jehovah’s Witness blood transfusion policy changed substantially in 2026. This portal brings together AJWRB’s principal clinical, bioethical, legal, epidemiological, and historical resources concerning Jehovah’s Witness medical policy. It is designed for clinicians, ethics professionals, attorneys, researchers, risk-management personnel, and others who need accurate information about blood-related treatment decisions.

Following major policy changes in March and September 2026, religious affiliation no longer establishes whether a patient will accept or refuse many major blood components or autologous procedures. Contemporary clinical practice therefore requires individualized discussion of the patient’s actual treatment preferences. 1,2,3

Current 2026 Blood Policy

As of September 18, 2026, red blood cells, white blood cells, plasma, and platelets obtained from another person are matters of individual conscience for Jehovah’s Witnesses. Whole blood from another person remains prohibited.2,4,5

The use of a patient’s own blood in medical and surgical care—including preoperative collection and storage—became an individual decision on March 20, 2026.1 Witnesses may also decide whether to donate blood when it is intended to be separated into components or fractions.4,5


Jehovah's Witness blood transfusion policy 2026 showing current blood component choices

Current Jehovah’s Witness blood transfusion policy following the March and September 2026 changes.

Clinical Guidance for the Jehovah’s Witness Blood Transfusion Policy

The Jehovah’s Witness blood transfusion policy now requires clinicians to distinguish organizational rules from the individual patient’s treatment choices. Clinicians should determine which specific components and procedures a patient accepts or refuses, provide current information about risks and alternatives, protect confidential decision-making, and review treatment preferences with the individual patient.3,4

Statement to Share With Jehovah’s Witness Patients

AJWRB’s plain-language statement explains the 2026 changes and the patient’s freedom to accept or refuse individual treatments. Clinicians can offer the printed PDF to patients, especially those who may have limited access to digital information, and review any questions privately without presuming what the patient will choose. Family members may also share it as an invitation to an informed conversation, without pressure.

Read the patient statement  |  Download the printable PDF

Principal Clinical Resource

Jehovah’s Witness Blood Policy: A Clinical Guide (2026)

Current clinical guide covering whole blood, red cells, white cells, plasma, platelets, fractions, autologous procedures, donation, advance directives, confidentiality, and Hospital Liaison Committees.

September 2026 Policy Change

Jehovah’s Witness Blood Policy 2026: Major September 18 Change

AJWRB’s analysis of the reclassification of the four primary blood components and the implications for patients, clinicians, confidentiality, and existing medical directives.

March 2026 Precursor

Jehovah’s Witnesses Blood Policy Change: Autologous Donation (2026) examines the March 20 change that made the medical and surgical use of a patient’s own blood a personal decision. It predates, and should now be read in light of, the broader September 18 policy change.1,2

Additional Clinical Resources

The 2026 changes are especially important for informed consent and advance-care planning. Existing Jehovah’s Witness directives may have been completed when treatments that are now matters of conscience were categorically prohibited.1,2,4 Organizational permission does not establish patient consent, and an older directive should not automatically be assumed to reflect a capable patient’s current wishes. Professional guidance emphasizes individualized review of a Jehovah’s Witness patient’s treatment preferences and the importance of confirming that those preferences remain current.3

Priority Resource During the 2026 Transition

The Evolution of the Jehovah’s Witness Advance Medical Directive and Implications for Informed Consent examines the history and clinical significance of the blood-refusal directive. Existing documents warrant particular attention while a revised Jehovah’s Witness directive is pending.

Epidemiological Data & Mortality Research

The following resources address the historical mortality burden associated with transfusion refusal. They should be interpreted in the context of the policy periods and clinical evidence on which they were based; the September 2026 policy change does not erase their historical significance.

Policy Evolution & Institutional History

Jehovah’s Witness medical policies have changed repeatedly over time. Understanding the history of the Jehovah’s Witness blood transfusion policy is important when interpreting older directives, publications, and patient expectations. Historical material also helps explain how earlier organizational rules shaped clinical practice and patients’ perception of medical treatment and risk. These resources document that history and should not be read as descriptions of the current September 2026 blood policy unless expressly stated.

Peer-Reviewed Medical & Bioethical Literature

The following publications provide clinical, epidemiological, and bioethical context for severe anemia, transfusion refusal, blood-conservation medicine, informed consent, confidentiality, and the historical evolution of Jehovah’s Witness blood policy. Older Jehovah’s Witness-specific publications describe the policy in effect when they were written and should therefore be read in historical context.

Selected Clinical and Transfusion Medicine Literature

Seeber P, Trentino KM, Murray K, Lucas M. A further update on mortality and morbidity in patients with very low hemoglobin levels who decline blood transfusion.
Transfusion. 2024;64(7):1198-1206. doi:10.1111/trf.17867.

Beliaev AM, Marshall RJ, Gordon M, et al. Clinical benefits and cost-effectiveness of allogeneic red-blood-cell transfusion in severe symptomatic anaemia.
Vox Sang. 2012;103:18-24. doi:10.1111/j.1423-0410.2011.01573.x.

Guinn NR, Cooter ML, Villalpando C, et al. Severe anemia associated with increased risk of death and myocardial ischemia in patients declining blood transfusion.
Transfusion. 2018;58:2290-2296. doi:10.1111/trf.14768.

Randi ML, Bertozzi I, Santarossa C, et al. Prevalence and causes of anemia in hospitalized patients: impact on diseases outcome.
J Clin Med. 2020;9:950. doi:10.3390/jcm9040950.

Carson JL, Stanworth SJ, Guyatt G, et al. Red blood cell transfusion: 2023 AABB International Guidelines.
JAMA. 2023;330:1892-1902. doi:10.1001/jama.2023.12914.

Webert KE, Zeller MP. The untransfusable patient.
Hematology Am Soc Hematol Educ Program. 2025;2025(1):191-198. doi:10.1182/hematology.2025000705.

Carson JL, Noveck H, Berlin JA, Gould SA. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion.
Transfusion. 2002;42(7):812-818. doi:10.1046/j.1537-2995.2002.00123.x.

Shander A, Javidroozi M, Naqvi S, et al. An update on mortality and morbidity in patients with very low postoperative hemoglobin levels who decline blood transfusion.
Transfusion. 2014;54(10 Pt 2):2688-2695. doi:10.1111/trf.12565.

Tobian AAR, Ness PM, Noveck H, Carson JL. Time course and etiology of death in patients with severe anemia.
Transfusion. 2009;49(7):1395-1399. doi:10.1111/j.1537-2995.2009.02134.x.

Posluszny JA Jr, Napolitano LM. How do we treat life-threatening anemia in a Jehovah’s Witness patient?
Transfusion. 2014;54(12):3026-3034. doi:10.1111/trf.12888.

Pattakos G, Koch CG, Brizzio ME, et al. Outcome of patients who refuse transfusion after cardiac surgery: a natural experiment with severe blood conservation.
Arch Intern Med. 2012;172(15):1154-1160. doi:10.1001/archinternmed.2012.2449.

Elder L. Coagulopathy after cardiopulmonary bypass in Jehovah’s Witness patients: management of and for the individual rather than the religious institution.
Anesth Analg. 2007;104(4):757-758. doi:10.1213/01.ane.0000255256.22554.e9. Editorial.

Sniecinski RM, Chen EP, Levy JH, Szlam F, Tanaka KA. Coagulopathy after cardiopulmonary bypass in Jehovah’s Witness patients: management of two cases using fractionated components and factor VIIa.
Anesth Analg. 2007;104(4):763-765. doi:10.1213/01.ane.0000250913.45299.f3.

Roberts N, James S, Delaney M, Fitzmaurice C. The global need and availability of blood products: a modelling study.
Lancet Haematol. 2019;6(12):e606-e615. doi:10.1016/S2352-3026(19)30200-5.

Yazer MH, Spinella PC, Bank EA, et al. THOR-AABB Working Party recommendations for a prehospital blood product transfusion program.
Prehosp Emerg Care. 2022;26(6):863-875. doi:10.1080/10903127.2021.1995089.

Doyle DJ. Blood transfusions and the Jehovah’s Witness patient.
Am J Ther. 2002;9(5):417-424. doi:10.1097/00045391-200209000-00009.

Bioethical and Policy Literature

Elder L. Why some Jehovah’s Witnesses accept blood and conscientiously reject official Watchtower Society blood policy.
J Med Ethics. 2000;26(5):375-380. doi:10.1136/jme.26.5.375.

Gillon R. Refusal of potentially life-saving blood transfusions by Jehovah’s Witnesses: should doctors explain that not all JWs think it’s religiously required?
J Med Ethics. 2000.

Muramoto O. Medical confidentiality and the protection of Jehovah’s Witnesses’ autonomous refusal of blood.
J Med Ethics. 2000;26(5):381-386. doi:10.1136/jme.26.5.381.

Muramoto O. Bioethical aspects of the recent changes in the policy of refusal of blood by Jehovah’s Witnesses.
BMJ. 2001;322(7277):37-39. doi:10.1136/bmj.322.7277.37.

Muramoto O. Bioethics of the refusal of blood by Jehovah’s Witnesses: Part 1. Should bioethical deliberation consider dissidents’ views?
J Med Ethics. 1998.

Muramoto O. Bioethics of the refusal of blood by Jehovah’s Witnesses: Part 2. A novel approach based on rational non-interventional paternalism.
J Med Ethics. 1998.

Muramoto O. Bioethics of the refusal of blood by Jehovah’s Witnesses: Part 3. A proposal for a don’t-ask-don’t-tell policy.
J Med Ethics. 1999.

Muramoto O. Recent developments in medical care of Jehovah’s Witnesses.
West J Med.

References

  1. Watch Tower Bible and Tract Society of Pennsylvania. 2026 Governing Body Update #2. March 20, 2026. Accessed September 19, 2026. JW.org.
  2. Watch Tower Bible and Tract Society of Pennsylvania. 2026 Governing Body Update #6. September 18, 2026. Accessed September 19, 2026. JW.org.
  3. American College of Surgeons Committee on Ethics. Statement on recommendations for surgeons caring for patients who are Jehovah’s Witnesses. September 1, 2018. Accessed September 19, 2026. American College of Surgeons.
  4. Watch Tower Bible and Tract Society of Pennsylvania. How do Jehovah’s Witnesses show respect for life? Accessed September 19, 2026. JW.org.
  5. Jehovah’s Witnesses. Jehovah’s Witnesses: Each Witness now decides whether to accept or donate main blood components. September 18, 2026. Accessed September 19, 2026. JW.org.

Professional use note: AJWRB resources are educational and are not substitutes for patient-specific medical advice, legal advice, institutional policy, or applicable law. Historical resources describe the policies and practices in effect during the periods discussed. For current care, clinicians should establish the individual patient’s contemporaneous treatment preferences.